Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Completed · Phase 3
Conditions studied: HIV Infections, Hepatitis C
In brief
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.
Key facts
- Study ID
- NCT01482767
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 262
- Starts
- 2012-04-01
- Expected to finish
- 2015-04-01
- Last updated by the study team
- 2021-11-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Alabama CRS — Birmingham, Alabama, United States
- University of Southern California CRS — Los Angeles, California, United States
- UCLA CARE Center CRS — Los Angeles, California, United States
- Stanford AIDS Clinical Trials Unit CRS — Palo Alto, California, United States
- UCSD Antiviral Research Center CRS — San Diego, California, United States
- Ucsf Hiv/Aids Crs — San Francisco, California, United States
- Harbor-UCLA CRS — Torrance, California, United States
- University of Colorado Hospital CRS — Aurora, Colorado, United States
- Denver Public Health CRS — Denver, Colorado, United States
- Georgetown University CRS (GU CRS) — Washington D.C., District of Columbia, United States
- The Ponce de Leon Center CRS — Atlanta, Georgia, United States
- Northwestern University CRS — Chicago, Illinois, United States
- Rush University CRS — Chicago, Illinois, United States
- IHV Baltimore Treatment CRS — Baltimore, Maryland, United States
- Johns Hopkins University CRS — Baltimore, Maryland, United States
- Massachusetts General Hospital CRS (MGH CRS) — Boston, Massachusetts, United States
- Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS — Boston, Massachusetts, United States
- Bmc Actg Crs — Boston, Massachusetts, United States
- Wayne State Univ. CRS — Detroit, Michigan, United States
- Henry Ford Hosp. CRS — Detroit, Michigan, United States
- Washington University Therapeutics (WT) CRS — St Louis, Missouri, United States
- Cooper Univ. Hosp. CRS — Camden, New Jersey, United States
- New Jersey Medical School Clinical Research Center CRS — Newark, New Jersey, United States
- Weill Cornell Chelsea CRS — New York, New York, United States
- Columbia P&S CRS — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.